International Cannabis Weekly: 153

• Prohibition Partners LIVE welcomes over 1,500 delegates to inaugural virtual event.
• UK government reclassifies Epidyolex as a Schedule 5 drug.
• Whistleblower claims US Attorney General falsely targeted ten cannabis companies.

• German cannabinoids’ sales climb to reach US$16.8 million in March.
• Is the CBD bubble about to burst?
• Leading professor says UK medicinal cannabis has reached an impasse on clinical trials.
• Swiss lawmakers to consider expanding medical cannabis access.
• British cannabis campaigners call on the government to improve patient access.
• Czech extraction facility receives approval to export full-spectrum hemp extract to Spain.
• CBDepot group announces new EU GMP compliant manufacturing site for CBD APIs.

Missed out on Prohibition Partners LIVE? Not to worry, you can access all 120 hours of virtual debate, market intelligence and consumer data via our on-demand platform.

We highly recommend watching Protecting the Consumer: CBD in Europe (Cannabis Europa), Building Successful Cannabis Brands (Cannabis Americana), and What Lies Ahead? The Future of Therapy (The PSYCH Symposium).

Access all the content now for 30 days for as little as $59 (£47/€53).

BUY NOW

• Canopy Growth reaches agreement to amend its deal to purchase Acreage Holdings.
• Veterans health commission recommends furthering cannabis & psychedelics research.
• Oklahoma Supreme Court clears cannabis legalisation measure for signature gathering.
• LA city council gives initial approval to cannabis social equity programme overhaul.
• Massachusetts posts lukewarm recreational cannabis sales for first week of reopening.
• New Jersey to phase out medical cannabis sales taxes by July 2022.
• MedMen loses provisional medical cannabis business licence in Virginia.

• Ontario cannabis market surpasses 100 cannabis retail store authorisations.
• Cannabis retail sales fall slightly 0.6% in April after stockpiling in March.
• Retailers in British Columbia seek approval for cannabis delivery.
• Aurora Cannabis to close five facilities and lay off 700 workers during restructuring.
• Canopy Growth to target cannabis-infused vapes and drinks in ‘bounce back’ effort.
• Regulators issue cease trade order for Sunniva pending overdue financial statements.

• British Virgin Islands projected to make annual US$30 million future cannabis exports.
• Colombia’s justice minister says cannabis is a financial opportunity post-coronavirus.

• Medical cannabis approvals show triple-digit annual growth in Australia.
• Australian TGA to review complaints of alleged non-compliant cannabis advertising.
• New Zealand’s Kāriki Pharma signs agreement paving way for exports to Germany.

• Israel’s Knesset plenum votes to advance two cannabis legalisation bills.
• South Africa cements new down-scheduled status of CBD and cannabis.
• Israel’s Univo imports cannabis from Lesotho and gains approval for Canadian imports.

• Epilepsy patients overwhelmingly prefer plant-derived CBD over synthetic equivalent.
• CBD reduces behavioural problems in children with intellectual disabilities, study finds.
• Women found to experience the same cannabis effects at a lower THC dosage than men.

• US military invests US$27 million in developing psychedelics-inspired drugs.
• New poll shows 59% of Canadians support legalising psilocybin use for the terminally ill.
• Iowa rejects psilocybin decriminalisation amendment in floor vote.
• Former Canadian health minister joins advisory board of Red Light Holland.
• MindMed files two patent applications for screening & optimising MDMA and LSD dosing.

Health insurance cannabis sales in Germany soared in Q1 2020, reaching a new record high of almost €15 million in March, more than 50% above the €9.5m of a year before.

The exceptionally good results in March 2020 may reflect some patients redeeming their prescriptions earlier to cope with the COVID-19 crisis, similar to the stockpiling seen in North American markets during March.

Read the full analysis from Prohibition Partners here.

READ NOW